RhumbLine Advisers’s Verrica Pharmaceuticals VRCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,494
| Closed | -$15.4K | – | 4269 |
|
|
2025
Q1 | $15.4K | Sell |
3,494
-23,115
| -87% | -$102K | ﹤0.01% | 3776 |
|
|
2024
Q4 | $186K | Buy |
26,609
+24,134
| +975% | +$169K | ﹤0.01% | 3234 |
|
|
2024
Q3 | $35.9K | Sell |
2,475
-184
| -7% | -$2.67K | ﹤0.01% | 3740 |
|
|
2024
Q2 | $194K | Buy |
2,659
+451
| +20% | +$32.9K | ﹤0.01% | 3239 |
|
|
2024
Q1 | $131K | Sell |
2,208
-31
| -1% | -$1.84K | ﹤0.01% | 3355 |
|
|
2023
Q4 | $164K | Sell |
2,239
-104
| -4% | -$7.61K | ﹤0.01% | 3277 |
|
|
2023
Q3 | $91K | Buy |
2,343
+291
| +14% | +$11.3K | ﹤0.01% | 3494 |
|
|
2023
Q2 | $118K | Buy |
+2,052
| New | +$118K | ﹤0.01% | 3456 |
|
|
2022
Q2 | – | Sell |
-1,277
| Closed | -$104K | – | 3247 |
|
|
2022
Q1 | $104K | Sell |
1,277
-58
| -4% | -$4.72K | ﹤0.01% | 2878 |
|
|
2021
Q4 | $122K | Buy |
1,335
+37
| +3% | +$3.38K | ﹤0.01% | 2916 |
|
|
2021
Q3 | $162K | Buy |
1,298
+14
| +1% | +$1.75K | ﹤0.01% | 2941 |
|
|
2021
Q2 | $145K | Sell |
1,284
-59
| -4% | -$6.66K | ﹤0.01% | 2947 |
|
|
2021
Q1 | $204K | Sell |
1,343
-66
| -5% | -$10K | ﹤0.01% | 2825 |
|
|
2020
Q4 | $162K | Buy |
1,409
+91
| +7% | +$10.5K | ﹤0.01% | 2892 |
|
|
2020
Q3 | $102K | Sell |
1,318
-214
| -14% | -$16.6K | ﹤0.01% | 2867 |
|
|
2020
Q2 | $169K | Sell |
1,532
-201
| -12% | -$22.2K | ﹤0.01% | 2829 |
|
|
2020
Q1 | $189K | Buy |
1,733
+10
| +0.6% | +$1.09K | ﹤0.01% | 2608 |
|
|
2019
Q4 | $274K | Buy |
1,723
+31
| +2% | +$4.93K | ﹤0.01% | 2639 |
|
|
2019
Q3 | $250K | Buy |
1,692
+90
| +6% | +$13.3K | ﹤0.01% | 2663 |
|
|
2019
Q2 | $186K | Buy |
1,602
+577
| +56% | +$67K | ﹤0.01% | 2805 |
|
|
2019
Q1 | $111K | Buy |
+1,025
| New | +$111K | ﹤0.01% | 2847 |
|